Literature DB >> 6197973

Epitope specific immunity elicited by a synthetic streptococcal antigen without carrier or adjuvant.

M Jolivet, F Audibert, E H Beachey, A Tartar, H Gras-Masse, L Chedid.   

Abstract

A polypeptide fragment of type 24 streptococcal M protein (pep M24) has been shown to raise protective anti-streptococcal antibodies in rabbits and humans when administered with adjuvants. More recently, such protective antibodies were shown to be evoked by a synthesized 35-residue sub-peptide fragment (S-CB7 synthetic cyanogen bromide fragment 7) of pep M24. We now show that the weak pep M24 immunogen induces high titers of long lasting antibodies when associated with murabutide, a synthetic derivative of MDP (NAcMur-L-Ala-D-Gln-n-butyl-ester) which is currently undergoing clinical trials. We demonstrate also that the polymerized synthetic S-CB7 administered without adjuvant or carrier evokes a strong epitope specific, protective immune response in mice primed with the parent pep M24. A booster dose of polymerized S-CB7 induced antibodies directed specifically against the S-CB7 structure whereas a booster dose of pep M24 evoked antibodies recognizing additional determinants of the whole pep M24 molecule.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6197973     DOI: 10.1016/0006-291x(83)91208-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier.

Authors:  L D Lise; D Mazier; M Jolivet; F Audibert; L Chedid; D Schlesinger
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

Review 2.  Streptococcal M protein: molecular design and biological behavior.

Authors:  V A Fischetti
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

3.  Induction of biologically active antibodies by a polyvalent synthetic vaccine constructed without carrier.

Authors:  M E Jolivet; F M Audibert; H Gras-Masse; A L Tartar; D H Schlesinger; R Wirtz; L A Chedid
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

4.  Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant.

Authors:  E H Beachey
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

5.  Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies.

Authors:  G M Bahr; D S Tello; L A Chedid
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

6.  Epitope-specific protective immunogenicity of chemically synthesized 13-, 18-, and 23-residue peptide fragments of streptococcal M protein.

Authors:  E H Beachey; A Tartar; J M Seyer; L Chedid
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

7.  New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP.

Authors:  L Chedid; F Audibert
Journal:  Springer Semin Immunopathol       Date:  1985

8.  Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens.

Authors:  F M Audibert; G Przewlocki; C D Leclerc; M E Jolivet; H S Gras-Masse; A L Tartar; L A Chedid
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

9.  Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative.

Authors:  E R Clough; F M Audibert; J W Barnwell; D H Schlesinger; R Arnon; L A Chedid
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

10.  Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem.

Authors:  E H Beachey; J M Seyer; J B Dale
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.